mChoice: Improving PrEP Uptake and Adherence among Minority MSM through Tailored Provider Training and Adherence Assistance in Two High Priority Settings
mChoice:通过在两个高度优先的环境中提供定制的提供者培训和依从性援助,提高少数族群 MSM 的 PrEP 接受度和依从性
基本信息
- 批准号:10324998
- 负责人:
- 金额:$ 103.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2026-09-29
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Men who have sex with men (MSM), especially young Black/African American (“Black”) and Hispanic/Latino
(“Latino”) MSM, have the highest rates of HIV diagnoses in the United States (US), illustrating the need for timely,
efficacious, and culturally congruent HIV prevention tools for these populations. One such tool is pre-exposure
prophylaxis (PrEP), which is one of the pillars to prevent new HIV infections in the Ending the HIV Epidemic: A
Plan for America initiative in the US. Increasing PrEP use by priority populations is an urgent HIV prevention
need. There are three PrEP options currently or soon to be available: 1) daily oral PrEP comprised of tenofovir
disoproxil fumarate and emtricitabine (TDF/FTC) or tenofovir alafenamide and emtricitabine (TAF/FTC), 2) 2-1-
1 dosing of TDF/FTC, and 3) bi-monthly injectable long-acting cabotegravir (CAB-LA), which is expected to
become available in as soon as a few months. Yet, uptake of PrEP is inverse to HIV acquisition risk among Black
and Latino young MSM who are less likely to access and adhere to PrEP than White and older MSM despite
being the highest risk group for acquiring HIV relative to other racial/ethnic and age groups. There are both
provider-level barriers to increasing PrEP screening, counseling, and initiation among priority populations and
patient-level barriers to adherence and persistence to PrEP. Therefore, our proposed study will target: 1)
provider-level barriers to optimal PrEP screening, counseling, and initiation through practice facilitation and a
provider training on culturally congruent PrEP options, and 2) patient-level barriers to PrEP adherence and
persistence through a mobile health (mHealth) tool (mChoice App). Building on the only CDC evidence-based
intervention for PrEP medication adherence/persistence, PrEPmate, and our own formative work with the CDC
(U01PS003715; PI: Schnall) to design and build a mHealth app and integrate it with a smart pill box (CleverCap),
the patient-level intervention, mChoice App, will enable oral PrEP users to self-monitor their medication
adherence in real-time; provide key information about PrEP choices, reminder messages about appointments,
videos, and testimonials of peers taking PrEP; and promote two-way communication between participants and
the study staff during the study. The practice facilitation intervention will comprise three phases: pre-
implementation planning, which will include provider training around culturally congruent PrEP options,
implementation with formative evaluation, and post-implementation summative evaluation. To assess the
effectiveness, we will conduct a Hybrid Type II trial simultaneously testing the effectiveness of a culturally
congruent clinical intervention (mChoice App) and an implementation intervention (practice facilitation) guided
by complementary implementation and evaluation frameworks–the Consolidated Framework for Implementation
Research (CFIR) and Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM). Findings
will have the potential to improve PrEP delivery for young Black and Latino MSM and, ultimately, decrease the
incidence of new HIV infections in two high-priority settings in the US, New York City and Birmingham, Alabama.
与男性发生性关系的男性(MSM),特别是年轻的黑人/非洲裔美国人(“黑人”)和西班牙裔/拉丁裔
(“拉丁裔”)男男性接触者,在美国艾滋病毒诊断率最高,说明需要及时,
为这些人群提供有效和文化上一致的艾滋病毒预防工具。其中一个工具就是预曝光
预防(PrEP),这是在结束艾滋病毒流行中预防新的艾滋病毒感染的支柱之一:A
美国的Plan for America计划。增加优先人群的PrEP使用是一项紧迫的艾滋病毒预防措施
需要的目前或即将推出的PrEP有三种选择:1)每日口服PrEP,由替诺福韦组成
富马酸二异山梨酯和恩曲他滨(TDF/FTC)或替诺福韦艾拉酚胺和恩曲他滨(TAF/FTC),2)2-1-
1次TDF/FTC给药,和3)每两个月注射一次长效卡博特拉韦(CAB-LA),预期
几个月后就可以上市了然而,PrEP的摄取与黑人中的艾滋病毒感染风险相反
和拉丁美洲年轻的男男性接触者谁是不太可能获得和坚持PrEP比白色和老年男男性接触者,尽管
与其他种族/族裔和年龄组相比,他们是感染艾滋病毒的最高风险群体。既有
在优先人群中增加PrEP筛查、咨询和启动的提供者层面的障碍,
患者层面的障碍,以遵守和坚持准备。因此,我们提出的研究将目标:1)
提供者层面的障碍,以最佳的PrEP筛查,咨询,并通过实践促进和启动
提供者在文化上一致的PrEP选项方面的培训,以及2)患者层面的PrEP依从性障碍,
通过移动的健康(mHealth)工具(mChoice App)实现持久性。基于CDC唯一的循证医学
PrEP药物依从性/持久性的干预,PrEPmate,以及我们自己与CDC的形成性工作
(U 01 PS 003715; PI:Schnall)设计和构建移动健康应用程序,并将其与智能药盒(CleverCap)集成,
患者层面的干预,mChoice应用程序,将使口服PrEP用户能够自我监测他们的药物
实时依从性;提供有关PrEP选择的关键信息,有关预约的提醒消息,
视频,和同行的推荐服用PrEP;并促进参与者之间的双向沟通,
研究期间的研究人员。实践促进干预将包括三个阶段:
实施规划,其中将包括围绕文化上一致的PrEP选项的提供者培训,
实施形成性评价和实施后总结性评价。评估
有效性,我们将进行混合II型试验,同时测试文化的有效性,
一致的临床干预(mChoice App)和实施干预(实践促进)指导
执行和评价框架-综合执行框架
研究(CFIR)和达到,有效性,采用,实施和维护(RE-AIM)。结果
将有可能改善年轻黑人和拉丁裔男男性接触者的PrEP交付,并最终减少
美国纽约市和亚拉巴马州伯明翰市两个高度优先环境中新发艾滋病毒感染的发病率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rebecca Schnall其他文献
Rebecca Schnall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rebecca Schnall', 18)}}的其他基金
Dissemination of the WiseApp for Improving Health Outcomes Across Settings
传播 WiseApp 以改善跨环境的健康结果
- 批准号:
10490284 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
Dissemination of the WiseApp for Improving Health Outcomes Across Settings
传播 WiseApp 以改善跨环境的健康结果
- 批准号:
10685304 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
mChoice: Improving PrEP Uptake and Adherence among Minority MSM through Tailored Provider Training and Adherence Assistance in Two High Priority Settings
mChoice:通过在两个高度优先的环境中提供定制的提供者培训和依从性援助,提高少数族群 MSM 的 PrEP 接受度和依从性
- 批准号:
10488047 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
mChoice: Improving PrEP Uptake and Adherence among Minority MSM through Tailored Provider Training and Adherence Assistance in Two High Priority Settings
mChoice:通过在两个高度优先的环境中提供定制的提供者培训和依从性援助,提高少数族群 MSM 的 PrEP 接受度和依从性
- 批准号:
10663097 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
Dissemination of the WiseApp for Improving Health Outcomes Across Settings
传播 WiseApp 以改善跨环境的健康结果
- 批准号:
10290733 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
Mentoring and Research in Self-Management for Health Promotion and Disease Prevention
健康促进和疾病预防自我管理的指导和研究
- 批准号:
10380063 - 财政年份:2019
- 资助金额:
$ 103.92万 - 项目类别:
Mentoring and Research in Self-Management for Health Promotion and Disease Prevention
健康促进和疾病预防自我管理的指导和研究
- 批准号:
9917843 - 财政年份:2019
- 资助金额:
$ 103.92万 - 项目类别:
The Wise App Trial for Improving Health Outcomes in PLWH
用于改善 PLWH 健康结果的 Wise 应用试验
- 批准号:
10013220 - 财政年份:2016
- 资助金额:
$ 103.92万 - 项目类别:
Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living with HIV
使用移动医疗技术支持服务不足的艾滋病毒感染者的症状管理
- 批准号:
8902295 - 财政年份:2015
- 资助金额:
$ 103.92万 - 项目类别:
Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms
HIV 相关非艾滋病 (VIP-HANA) 症状视频信息提供者
- 批准号:
9111067 - 财政年份:2015
- 资助金额:
$ 103.92万 - 项目类别:
相似国自然基金
Improving modelling of compact binary evolution.
- 批准号:10903001
- 批准年份:2009
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
相似海外基金
RSV I-PREP: Improving Evidence-Based Implementation of RSV Immuno-Prophylaxis Within Ethical and Policy Contexts
RSV I-PREP:在伦理和政策背景下改进 RSV 免疫预防的循证实施
- 批准号:
10739713 - 财政年份:2023
- 资助金额:
$ 103.92万 - 项目类别:
Improving HIV testing and PrEP for transgender women through mHealth
通过移动医疗改善跨性别女性的艾滋病毒检测和 PrEP
- 批准号:
10258220 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
mChoice: Improving PrEP Uptake and Adherence among Minority MSM through Tailored Provider Training and Adherence Assistance in Two High Priority Settings
mChoice:通过在两个高度优先的环境中提供定制的提供者培训和依从性援助,提高少数族群 MSM 的 PrEP 接受度和依从性
- 批准号:
10488047 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
mChoice: Improving PrEP Uptake and Adherence among Minority MSM through Tailored Provider Training and Adherence Assistance in Two High Priority Settings
mChoice:通过在两个高度优先的环境中提供定制的提供者培训和依从性援助,提高少数族群 MSM 的 PrEP 接受度和依从性
- 批准号:
10663097 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
Improving HIV testing and PrEP for transgender women through mHealth
通过移动医疗改善跨性别女性的艾滋病毒检测和 PrEP
- 批准号:
10398983 - 财政年份:2021
- 资助金额:
$ 103.92万 - 项目类别:
Improving the HIV PrEP Cascade using an Intervention for Healthcare Providers
使用医疗保健提供者干预措施改善 HIV PrEP 级联
- 批准号:
10176701 - 财政年份:2020
- 资助金额:
$ 103.92万 - 项目类别:
Improving PrEP protection of transgender women through mechanistic pharmacokinetic understanding
通过机制药代动力学理解改善跨性别女性的 PrEP 保护
- 批准号:
10355444 - 财政年份:2019
- 资助金额:
$ 103.92万 - 项目类别:
Improving PrEP protection of transgender women through mechanistic pharmacokinetic understanding
通过机制药代动力学理解改善跨性别女性的 PrEP 保护
- 批准号:
9891005 - 财政年份:2019
- 资助金额:
$ 103.92万 - 项目类别:
A Structural Approach to Improving HIV Pre-Exposure Prophylaxis (PrEP) Implementation among High Risk Men
改善高危男性 HIV 暴露前预防 (PrEP) 实施的结构性方法
- 批准号:
10171915 - 财政年份:2018
- 资助金额:
$ 103.92万 - 项目类别:
Improving the HIV PrEP Cascade using an Intervention for Healthcare Providers
使用医疗保健提供者干预措施改善 HIV PrEP 级联
- 批准号:
10406498 - 财政年份:2017
- 资助金额:
$ 103.92万 - 项目类别: